Vascular endothelial growth factor (VEGF)-C can induce controlled lymphatic recovery after injury.10 Thus, VEGF-C pathological models are important for understanding the pathogenesis of CLAs.11–13 Recent studies have investigated lymphangiogenesis and lymphatic vasculature remodeling and suggested that genetic abnormalities in the RAS/mitogen-activated protein (MAPK) and phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathways could be responsible for these lymphatic diseases.14–18. The gene discussed is VEGFC; the disease is lymphatic system disorder.